{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:37:13Z","timestamp":1790721433360,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic retinopathy frequently coexists with secondary epiretinal membrane (ERM), which may interfere with therapeutic responses in diabetic macular edema (DME). However, consensus on optimal management for DME with concomitant ERM is lacking. This study compared the short-term therapeutic effects of intravitreal dexamethasone (DEX) implants and anti-VEGF agents in DME eyes with ERM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 109 eyes of 71 patients treated with either intravitreal anti-VEGF or DEX implant for DME between January 2014 and December 2022. Pre-treatment optical coherence tomography was reviewed. Best-corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded at baseline, 2 months, and 4 months after treatment. The primary outcomes were changes in BCVA and CMT between baseline and follow-up after DEX or anti-VEGF therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      DEX provided a significantly greater relative reduction in CMT for DME eyes with ERM (\u03b2 = \u2212\u200915.675% [5.0]), while no significant difference was observed in eyes without ERM compared to anti-VEGF. Anti-VEGF therapy resulted in significantly less CMT reduction in eyes with ERM than in those without ERM (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). DEX implantation led to significant BCVA improvement versus anti-VEGF in DME with ERM (OR\u2009=\u20095.287; 95% CI, 1.100\u201325.417), whereas no significant difference was found in eyes without ERM (OR\u2009=\u20091.128; 95% CI, 0.232\u20135.493).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DEX therapy achieved superior short-term anatomical and functional outcomes compared to anti-VEGF in DME with ERM, supporting its consideration as a first-line treatment option in this subgroup.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00788-w","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T06:14:13Z","timestamp":1767420853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dexamethasone implant vs. anti-VEGF for diabetic macular edema with epiretinal membrane: short-term outcomes"],"prefix":"10.1186","volume":"12","author":[{"given":"Yung-Ching","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Cheng","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Yueh","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"4","key":"788_CR1","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.survophthal.2022.01.009","volume":"67","author":"JHB Im","year":"2022","unstructured":"Im JHB, Jin YP, Chow R, Yan P. Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: A systematic review and meta-analysis. Surv Ophthalmol. 2022;67(4):1244\u201351.","journal-title":"Surv Ophthalmol"},{"key":"788_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.phrs.2015.11.003","volume":"103","author":"S Fogli","year":"2016","unstructured":"Fogli S, Mogavero S, Egan CG, Del Re M, Danesi R. Pathophysiology and Pharmacological targets of Vegf in diabetic macular edema. Pharmacol Res. 2016;103:149\u201357.","journal-title":"Pharmacol Res"},{"issue":"5","key":"788_CR3","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.survophthal.2022.04.001","volume":"67","author":"K Madjedi","year":"2022","unstructured":"Madjedi K, Pereira A, Ballios BG, Arjmand P, Kertes PJ, Brent M, et al. Switching between anti-vegf agents in the management of refractory diabetic macular edema: A systematic review. Surv Ophthalmol. 2022;67(5):1364\u201372.","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"788_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ophtha.2017.08.031","volume":"125","author":"D Zur","year":"2018","unstructured":"Zur D, Iglicki M, Busch C, Invernizzi A, Mariussi M, Loewenstein A, et al. Oct biomarkers as functional outcome predictors in diabetic macular edema treated with dexamethasone implant. Ophthalmology. 2018;125(2):267\u201375.","journal-title":"Ophthalmology"},{"issue":"4","key":"788_CR5","doi-asserted-by":"publisher","first-page":"e540","DOI":"10.1111\/aos.13935","volume":"97","author":"V Bonfiglio","year":"2019","unstructured":"Bonfiglio V, Reibaldi M, Pizzo A, Russo A, Macchi I, Faro G, et al. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers. Acta Ophthalmol. 2019;97(4):e540\u20134.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"788_CR6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/IAE.0000000000001687","volume":"38","author":"AR Santos","year":"2018","unstructured":"Santos AR, Costa M, Schwartz C, Alves D, Figueira J, Silva R, et al. Optical coherence tomography baseline predictors for initial best-corrected visual acuity response to intravitreal anti-vascular endothelial growth factor treatment in eyes with diabetic macular edema: the Chartres study. Retina. 2018;38(6):1110\u20139.","journal-title":"Retina"},{"issue":"3","key":"788_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/JCMA.0000000000000483","volume":"84","author":"J-K Wang","year":"2021","unstructured":"Wang J-K, Huang T-L, Hsu Y-R, Chang P-Y. Effect of dexamethasone intravitreal implant for refractory and treatment-naive diabetic macular edema in Taiwanese patients. J Chin Med Association. 2021;84(3):326\u201330.","journal-title":"J Chin Med Association"},{"issue":"4","key":"788_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4103\/tjo.tjo_68_19","volume":"9","author":"J Chawan-Saad","year":"2019","unstructured":"Chawan-Saad J, Wu M, Wu A, Wu L. Corticosteroids for diabetic macular edema. Taiwan J Ophthalmol. 2019;9(4):233\u201342.","journal-title":"Taiwan J Ophthalmol"},{"key":"788_CR9","doi-asserted-by":"crossref","unstructured":"Mitchell P, Arnold J, Fraser-Bell S, Kang HK, Chang AA, Tainton J et al. Dexamethasone intravitreal implant in diabetic macular oedema refractory to anti-vascular endothelial growth factors: the aussiedex study. BMJ Open Ophthalmol. 2023;8(1).","DOI":"10.1136\/bmjophth-2022-001224"},{"key":"788_CR10","doi-asserted-by":"publisher","first-page":"649979","DOI":"10.3389\/fmed.2021.649979","volume":"8","author":"NY Hsia","year":"2021","unstructured":"Hsia NY, Lin CJ, Chen HS, Chang CH, Bair H, Lai CT, et al. Short-term outcomes of refractory diabetic macular edema switch from Ranibizumab to dexamethasone implant and the influential factors: A retrospective real world experience. Front Med. 2021;8:649979.","journal-title":"Front Med"},{"issue":"1","key":"788_CR11","doi-asserted-by":"publisher","first-page":"7428","DOI":"10.1038\/s41598-023-34673-z","volume":"13","author":"SC Chi","year":"2023","unstructured":"Chi SC, Kang YN, Huang YM. Efficacy and safety profile of intravitreal dexamethasone implant versus antivascular endothelial growth factor treatment in diabetic macular edema: A systematic review and meta-analysis. Sci Rep. 2023;13(1):7428.","journal-title":"Sci Rep"},{"issue":"2","key":"788_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3928\/23258160-20170130-10","volume":"48","author":"Z Khan","year":"2017","unstructured":"Khan Z, Kuriakose RK, Khan M, Chin EK, Almeida DR. Efficacy of the intravitreal sustained-release dexamethasone implant for diabetic macular edema refractory to anti-vascular endothelial growth factor therapy: Meta-analysis and clinical implications. Ophthalmic Surg Lasers Imaging Retina. 2017;48(2):160\u20136.","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"3","key":"788_CR13","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1177\/11206721211024804","volume":"32","author":"AV Bux","year":"2022","unstructured":"Bux AV, Fortunato F, Barone A, Russo V, Delle Noci N, Iaculli C. Early treatment with dexamethasone intravitreal implants in diabetic macular edema: Na\u00efve versus refractory patients. Eur J Ophthalmol. 2022;32(3):1619\u201326.","journal-title":"Eur J Ophthalmol"},{"issue":"3","key":"788_CR14","first-page":"371","volume":"101","author":"N Cheung","year":"2017","unstructured":"Cheung N, Tan SP, Lee SY, Cheung GCM, Tan G, Kumar N, et al. Prevalence and risk factors for epiretinal membrane: the Singapore epidemiology of eye disease study. Br J Ophthalmol. 2017;101(3):371\u20136.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"788_CR15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.ophtha.2010.08.009","volume":"118","author":"CH Ng","year":"2011","unstructured":"Ng CH, Cheung N, Wang JJ, Islam AF, Kawasaki R, Meuer SM, et al. Prevalence and risk factors for epiretinal membranes in a multi-ethnic united States population. Ophthalmology. 2011;118(4):694\u20139.","journal-title":"Ophthalmology"},{"key":"788_CR16","doi-asserted-by":"publisher","first-page":"1108097","DOI":"10.3389\/fendo.2023.1108097","volume":"14","author":"TC Hsieh","year":"2023","unstructured":"Hsieh TC, Deng GH, Chang YC, Chang FL, He MS. A real-world study for timely assessing the diabetic macular edema refractory to intravitreal anti-vegf treatment. Front Endocrinol (Lausanne). 2023;14:1108097.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"788_CR17","doi-asserted-by":"publisher","first-page":"103555","DOI":"10.1016\/j.pdpdt.2023.103555","volume":"42","author":"Y Gong","year":"2023","unstructured":"Gong Y, Wang M, Li Q, Shao Y, Li X. Evaluating the effect of vitreomacular interface abnormalities on anti-vascular endothelial growth factor treatment outcomes in diabetic macular edema by optical coherence tomography: A systematic review and meta-analysis. Photodiagn Photodyn Ther. 2023;42:103555.","journal-title":"Photodiagn Photodyn Ther"},{"issue":"1","key":"788_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/jop.2011.0070","volume":"28","author":"PC Wu","year":"2012","unstructured":"Wu PC, Lai CH, Chen CL, Kuo CN. Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment. J Ocul Pharmacol Ther. 2012;28(1):59\u201364.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"8","key":"788_CR19","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s00417-018-4009-6","volume":"256","author":"M Mikhail","year":"2018","unstructured":"Mikhail M, Stewart S, Seow F, Hogg R, Lois N. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-vegf therapy. Graefe\u2019s Archive Clin Experimental Ophthalmol = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie. 2018;256(8):1411\u20138.","journal-title":"Graefe\u2019s Archive Clin Experimental Ophthalmol = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie"},{"issue":"5","key":"788_CR20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1089\/jop.2019.0133","volume":"36","author":"B Erden","year":"2020","unstructured":"Erden B, \u00c7ak\u0131r A, B\u00f6l\u00fckba\u015f\u0131 S, \u00d6zturan \u015eG, El\u00e7io\u011flu MN. The effects of epiretinal membranes on the treatment outcomes of dexamethasone implants in diabetic macular edema: A real-life study. J Ocul Pharmacol Ther. 2020;36(5):298\u2013303.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"7","key":"788_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jfo.2019.02.007","volume":"42","author":"A Cakir","year":"2019","unstructured":"Cakir A, Erden B, Bolukbasi S, Aydin A, Yurttaser Ocak S, Maden G, et al. Comparison of the effect of Ranibizumab and dexamethasone implant in diabetic macular edema with concurrent epiretinal membrane. J Fr Ophtalmol. 2019;42(7):683\u20139.","journal-title":"J Fr Ophtalmol"},{"issue":"1","key":"788_CR22","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1167\/iovs.10-5285","volume":"52","author":"J-E Chang-Lin","year":"2011","unstructured":"Chang-Lin J-E, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Investig Ophthalmol Vis Sci. 2011;52(1):80\u20136.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"1","key":"788_CR23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/IAE.0000000000002110","volume":"39","author":"PU Dugel","year":"2019","unstructured":"Dugel PU, Campbell JH, Kiss S, Loewenstein A, Shih V, Xu X, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of protocol i study data. Retina (Philadelphia Pa). 2019;39(1):88\u201397.","journal-title":"Retina (Philadelphia Pa)"},{"key":"788_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/OPTH.S128509","volume":"11","author":"KJ Blinder","year":"2017","unstructured":"Blinder KJ, Dugel PU, Chen S, Jumper JM, Walt JG, Hollander DA, et al. Anti-vegf treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (echo study report 1). Clin Ophthalmol. 2017;11:393\u2013401.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"788_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/bjophthalmol-2016-309313","volume":"101","author":"C Egan","year":"2017","unstructured":"Egan C, Zhu H, Lee A, Sim D, Mitry D, Bailey C, et al. The united Kingdom diabetic retinopathy electronic medical record users group, report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of Ranibizumab for diabetic macular oedema. Br J Ophthalmol. 2017;101(1):75\u201380.","journal-title":"Br J Ophthalmol"},{"key":"788_CR26","doi-asserted-by":"publisher","first-page":"1121270","DOI":"10.3389\/fmed.2023.1121270","volume":"10","author":"MK O\u017c\u00f3g","year":"2023","unstructured":"O\u017c\u00f3g MK, Nowak-W\u0105s M, Rokicki W. Pathophysiology and clinical aspects of epiretinal membrane - review. Front Med. 2023;10:1121270.","journal-title":"Front Med"},{"issue":"6","key":"788_CR27","doi-asserted-by":"publisher","first-page":"373","DOI":"10.5935\/0004-2749.20160106","volume":"79","author":"NY Ercalik","year":"2016","unstructured":"Ercalik NY, Imamoglu S, Kumral ET, Yenerel NM, Bardak H, Bardak Y. Influence of the epiretinal membrane on Ranibizumab therapy outcomes in patients with diabetic macular edema. Arquivos Brasileiros De Oftalmologia. 2016;79(6):373\u20135.","journal-title":"Arquivos Brasileiros De Oftalmologia"},{"issue":"4","key":"788_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00417-016-3562-0","volume":"255","author":"Y Wong","year":"2017","unstructured":"Wong Y, Steel DHW, Habib MS, Stubbing-Moore A, Bajwa D, Avery PJ. Vitreoretinal interface abnormalities in patients treatedwith Ranibizumab for diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol. 2017;255(4):733\u201342.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"788_CR29","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jcjo.2013.11.012","volume":"49","author":"MP Simunovic","year":"2014","unstructured":"Simunovic MP, Hunyor AP, Ho IV. Vitrectomy for diabetic macular edema: A systematic review and meta-analysis. Can J Ophthalmol. 2014;49(2):188\u201395.","journal-title":"Can J Ophthalmol"},{"issue":"5","key":"788_CR30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1159\/000524742","volume":"245","author":"G Rabina","year":"2022","unstructured":"Rabina G, Hilely A, Barequet D, Cohen S, Lipin N, Mimouni M, et al. Epiretinal membrane in patients with diabetic macular edema. Ophthalmol J Int D\u2019ophtalmologie Int J Ophthalmol Z Fur Augenheilkunde. 2022;245(5):446\u201354.","journal-title":"Ophthalmol J Int D\u2019ophtalmologie Int J Ophthalmol Z Fur Augenheilkunde"},{"issue":"1","key":"788_CR31","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12886-021-02095-y","volume":"21","author":"D Ivastinovic","year":"2021","unstructured":"Ivastinovic D, Haas A, Weger M, Seidel G, Mayer-Xanthaki C, Lindner E, et al. Vitrectomy for diabetic macular edema and the relevance of external limiting membrane. BMC Ophthalmol. 2021;21(1):334.","journal-title":"BMC Ophthalmol"},{"issue":"5","key":"788_CR32","doi-asserted-by":"publisher","first-page":"e0197065","DOI":"10.1371\/journal.pone.0197065","volume":"13","author":"MR Romano","year":"2018","unstructured":"Romano MR, Ilardi G, Ferrara M, Cennamo G, Allegrini D, Pafundi PC, et al. Intraretinal changes in idiopathic versus diabetic epiretinal membranes after macular peeling. PLoS ONE. 2018;13(5):e0197065.","journal-title":"PLoS ONE"},{"issue":"11","key":"788_CR33","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.1167\/iovs.14-15971","volume":"56","author":"SC Bu","year":"2015","unstructured":"Bu SC, Kuijer R, van der Worp RJ, Postma G, Renardel de Lavalette VW, Li XR, et al. Immunohistochemical evaluation of idiopathic epiretinal membranes and in vitro studies on the effect of tgf-\u03b2 on m\u00fcller cells. Investig Ophthalmol Vis Sci. 2015;56(11):6506\u201314.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"5","key":"788_CR34","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00125-003-1084-x","volume":"46","author":"Y Mitamura","year":"2003","unstructured":"Mitamura Y, Harada T, Harada C, Ohtsuka K, Kotake S, Ohno S, et al. Nf-\u03bab in epiretinal membranes after human diabetic retinopathy. Diabetologia. 2003;46(5):699\u2013703.","journal-title":"Diabetologia"},{"issue":"6","key":"788_CR35","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1023\/A:1021412601538","volume":"26","author":"FQ Wen","year":"2002","unstructured":"Wen FQ, Kohyama T, Sk\u00f6ld CM, Zhu YK, Liu X, Romberger DJ, et al. Glucocorticoids modulate tgf-beta production. Inflammation. 2002;26(6):279\u201390.","journal-title":"Inflammation"},{"issue":"1","key":"788_CR36","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12871-023-02277-9","volume":"23","author":"R He","year":"2023","unstructured":"He R, Li X, Zhang S, Liu Y, Xue Q, Luo Y, et al. Dexamethasone inhibits il-8 via Glycolysis and mitochondria-related pathway to regulate inflammatory pain. BMC Anesthesiol. 2023;23(1):317.","journal-title":"BMC Anesthesiol"},{"key":"788_CR37","doi-asserted-by":"publisher","first-page":"1233318","DOI":"10.3389\/fimmu.2023.1233318","volume":"14","author":"JJ Engel","year":"2023","unstructured":"Engel JJ, van der Made CI, Keur N, Setiabudiawan T, R\u00f6ring RJ, Damoraki G, et al. Dexamethasone attenuates interferon-related cytokine hyperresponsiveness in covid-19 patients. Front Immunol. 2023;14:1233318.","journal-title":"Front Immunol"},{"issue":"3","key":"788_CR38","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00210-020-02035-5","volume":"394","author":"M Kandasamy","year":"2021","unstructured":"Kandasamy M. Nf-\u03bab signalling as a Pharmacological target in covid-19: potential roles for ikk\u03b2 inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(3):561\u20137.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"788_CR39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/ceo.13914","volume":"49","author":"AT Fung","year":"2021","unstructured":"Fung AT, Galvin J, Tran T. Epiretinal membrane: A review. Clin Exp Ophthalmol. 2021;49(3):289\u2013308.","journal-title":"Clin Exp Ophthalmol"},{"issue":"10","key":"788_CR40","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1038\/eye.2010.80","volume":"24","author":"A Ophir","year":"2010","unstructured":"Ophir A, Martinez MR, Mosqueda P, Trevino A. Vitreous traction and epiretinal membranes in diabetic macular oedema using spectral-domain optical coherence tomography. Eye (Lond). 2010;24(10):1545\u201353.","journal-title":"Eye (Lond)"},{"issue":"10","key":"788_CR41","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1136\/bjo.81.10.919","volume":"81","author":"YS Chen","year":"1997","unstructured":"Chen YS, Hackett SF, Schoenfeld CL, Vinores MA, Vinores SA, Campochiaro PA. Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes. Br J Ophthalmol. 1997;81(10):919\u201326.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"788_CR42","doi-asserted-by":"publisher","first-page":"2942","DOI":"10.1167\/iovs.19-26788","volume":"60","author":"R Namba","year":"2019","unstructured":"Namba R, Kaneko H, Suzumura A, Shimizu H, Kataoka K, Takayama K, et al. In vitro epiretinal membrane model and antibody permeability: relationship with anti-vegf resistance in diabetic macular edema. Investig Ophthalmol Vis Sci. 2019;60(8):2942\u20139.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"1","key":"788_CR43","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2337\/db06-0581","volume":"56","author":"T Kita","year":"2007","unstructured":"Kita T, Hata Y, Kano K, Miura M, Nakao S, Noda Y, et al. Transforming growth factor-\u03b22 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor. Diabetes. 2007;56(1):231\u20138.","journal-title":"Diabetes"},{"issue":"3","key":"788_CR44","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/bjo.2009.177287","volume":"95","author":"J Marticorena","year":"2011","unstructured":"Marticorena J, Romano MR, Heimann H, Stappler T, Gibran K, Groenewald C, et al. Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: A possible secondary effect? Br J Ophthalmol. 2011;95(3):391\u20135.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"788_CR45","doi-asserted-by":"publisher","first-page":"100733","DOI":"10.1016\/j.xops.2025.100733","volume":"5","author":"S Kakihara","year":"2025","unstructured":"Kakihara S, AbdelSalam M, Zhuang K, Fawzi AA. Epiretinal membrane is associated with diabetic retinopathy severity and cumulative anti-vegf injections. Ophthalmol Sci. 2025;5(3):100733.","journal-title":"Ophthalmol Sci"},{"issue":"7","key":"788_CR46","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1097\/IAE.0000000000001369","volume":"37","author":"A Malcl\u00e8s","year":"2017","unstructured":"Malcl\u00e8s A, Dot C, Voirin N, Vi\u00e9 AL, Agard \u00c9, Bellocq D, et al. Safety of intravitreal dexamethasone implant (ozurdex): the Safodex study. Incidence and risk factors of ocular hypertension. Retina (Philadelphia Pa). 2017;37(7):1352\u20139.","journal-title":"Retina (Philadelphia Pa)"},{"issue":"1","key":"788_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12886-018-0779-1","volume":"18","author":"Y He","year":"2018","unstructured":"He Y, Ren XJ, Hu BJ, Lam WC, Li XR. A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmol. 2018;18(1):121.","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"788_CR48","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.ophtha.2015.12.012","volume":"123","author":"S Fraser-Bell","year":"2016","unstructured":"Fraser-Bell S, Lim LL, Campain A, Mehta H, Aroney C, Bryant J, et al. Bevacizumab or dexamethasone implants for dme: 2-year results (the Bevordex study). Ophthalmology. 2016;123(6):1399\u2013401.","journal-title":"Ophthalmology"},{"issue":"8","key":"788_CR49","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00592-018-1151-x","volume":"55","author":"C Busch","year":"2018","unstructured":"Busch C, Zur D, Fraser-Bell S, La\u00edns I, Santos AR, Lupidi M, et al. Shall we stay, or shall we switch? Continued anti-vegf therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018;55(8):789\u201396.","journal-title":"Acta Diabetol"},{"issue":"9","key":"788_CR50","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamaophthalmol.2019.1963","volume":"137","author":"NM Bressler","year":"2019","unstructured":"Bressler NM, Odia I, Maguire M, Glassman AR, Jampol LM, MacCumber MW, et al. Association between change in visual acuity and change in central subfield thickness during treatment of diabetic macular edema in participants randomized to aflibercept, bevacizumab, or ranibizumab: A post hoc analysis of the protocol t randomized clinical trial. JAMA Ophthalmol. 2019;137(9):977\u201385.","journal-title":"JAMA Ophthalmol"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00788-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:01:24Z","timestamp":1781625684000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00788-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00788-w","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of the Research Ethics Committee of Hualien Tzu-Chi Hospital and Buddhist Tzu-Chi Medical Foundation (IRB113-033-B).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}